PF-04217903

PF-04217903 is a highly selective, orally administered, ATP-competitive small molecule inhibitor of the c-Met (hepatocyte growth factor receptor) tyrosine kinase. It binds to and inhibits c-Met, disrupting downstream signaling pathways involved in tumor cell proliferation, survival, migration, and invasion. The drug has demonstrated over 1,000-fold selectivity for c-Met compared to more than 150 other kinases. Preclinical studies showed that PF-04217903 inhibits tumor growth in models with MET gene amplification or an HGF/c-Met autocrine loop and exhibits antiangiogenic properties. Developed by Pfizer for oncology indications such as advanced solid tumors and mouth cancer, it reached Phase 1 clinical trials but was not approved for any indication[1][2][5][6][7].